REMODEL

CompletedPhase 3Results posted

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

106

actual

Study population

Chronic kidney disease, Type 2 diabetes

Key I/E criteria

•eGFR ≥30•UACR ≥20

Primary endpoints

•Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic•Kidney Oxygenation (Medulla), BOLD MRI (R2*)•Global Kidney Perfusion (MRI)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04865770

Org study IDNN9535-4662

Secondary ID2020-000828-19

Secondary IDU1111-1248-7912World Health Organization (WHO)

Timeline

Milestones

Study start2021-04-28actual

Study first posted2021-04-29actual

Primary completion2024-11-21actual

Study completion2024-11-21actual

Results first posted2026-01-14actual

Last update posted2026-02-10actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Chronic kidney diseaseType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or female.

•Age above or equal to 18 years at the time of signing informed consent.

•Diagnosed with T2D (type 2 diabetes) greater than or equal to 180 days prior to the day of screening.

•HbA1c (glycated haemoglobin) below or equal to 9.0 percent (below or equal to 75 mmol/mol).

•Depending on biopsy/non-biopsy population:

1. For subjects in the non-biopsy population: Serum creatinine-based eGFR greater than or equal to 30 and below or equal to 75 mL/min/1.73 m^2(CKD-EPI).

2. For subjects in the biopsy sub-population: Serum creatinine-based eGFR greater than or equal to 40 and below or equal to 75 mL/min/1.73 m^2(CKD-EPI).

•UACR ( Urinary albumin-to-creatinine ratio ) greater than or equal to 20 and below 5000 mg/g.

•Treatment with maximum labelled or tolerated dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB)) unless such treatment is contraindicated or not tolerated.Treatment dose must be stable for at least 28 days prior to screening.

Exclusion criteria

•Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA) within 30 days prior to screening.

•A prior solid organ transplant or awaiting solid organ transplant.

•Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening.

•Presence or history of malignant neoplasms (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) within 5 years prior to the day of screening.

•Congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations.

•Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and Visit 2. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

•Treatment with systemic anti-inflammatory or immunosuppressant drugs within 90 days prior to screening. Stable treatment with acetylsalicylic acid for prevention of cardiovascular events and occasional use of propionic acid derivatives drugs (e.g. ibuprofen) is allowed.

•Any contraindication for MRI according to standard checklist used in clinical routine, including claustrophobia or metallic foreign bodies, metallic implants, internal electrical devices, or permanent makeup/tattoos that cannot be declared MR compatible.

•Combination use of an ACE (angiotensin-converting enzyme) inhibitor and an ARB (angiotensin II receptor blockers).

Endpoints (28)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Renal / kidney

Other (unclassified)

Renal / kidney

22 endpoints

Primary/registry result

Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Posted result

Group	Value (geometric_mean), Ratio of kidney oxygenation (cortex)	95% CI
Semaglutide 1.0 mgBilateral cortex	0.98	—
Right cortex	0.98	—
Left cortex	0.98	—
PlaceboBilateral cortex	1.00	—
Right cortex	0.99	—
Left cortex	1.01	—

Treatment ratio0.9895% CI0.96 – 1.01p0.1333ANCOVA

Bilateral cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate, on log scale.

Treatment ratio0.9995% CI0.96 – 1.01p0.2487ANCOVA

Right cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate, on log scale.

Treatment ratio0.9795% CI0.94 – 1.00p0.0907ANCOVA

Left cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate, on log scale.

Primary/registry result

Change in Kidney Oxygenation (Medulla), BOLD MRI (R2*)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Posted result

Group	Value (geometric_mean), Ratio of kidney oxygenation (medulla)	95% CI
Semaglutide 1.0 mgBilateral medulla	0.99	—
Right medulla	0.98	—
Left medulla	0.99	—
PlaceboBilateral medulla	1.01	—
Right medulla	1.02	—
Left medulla	1.02	—

Treatment ratio0.9995% CI0.94 – 1.03p0.5619ANCOVA

Bilateral medulla: The responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Treatment ratio0.9795% CI0.93 – 1.02p0.2774ANCOVA

Right medulla: The responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Treatment ratio0.9995% CI0.94 – 1.04p0.7924ANCOVA

Left medulla: The responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Primary/registry result

Change in Global Kidney Perfusion (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Posted result

Group	Value (geometric_mean), Ratio of global kidney perfusion	95% CI
Semaglutide 1.0 mgBilateral kidney	1.03	—
Right kidney	1.04	—
Left kidney	1.02	—
PlaceboBilateral kidney	0.99	—
Right kidney	0.98	—
Left kidney	1.01	—

Treatment ratio1.1095% CI0.98 – 1.24p0.0958ANCOVA

Bilateral kidney: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Treatment ratio1.1795% CI1.03 – 1.33p0.0145ANCOVA

Right kidney: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Treatment ratio1.0695% CI0.94 – 1.21p0.3311ANCOVA

Left kidney: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Primary/registry result

Change in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of kidney inflammation (cortex)	95% CI
Semaglutide 1.0 mgBilateral cortex	1.01	—
Right cortex	1.01	—
Left cortex	1.01	—
PlaceboBilateral cortex	1.01	—
Right cortex	1.01	—
Left cortex	1.01	—

Treatment ratio1.0095% CI0.98 – 1.02p0.8651ANCOVA

Bilateral cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Treatment ratio1.0095% CI0.98 – 1.02p0.7240ANCOVA

Right cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Treatment ratio1.0095% CI0.98 – 1.02p0.7195ANCOVA

Left cortex: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Primary/registry result

Change in Kidney Inflammation (Medulla), T1 Mapping (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

ratio, improvement

Posted result

Group	Value (geometric_mean), Ratio of kidney inflammation (medulla)	95% CI
Semaglutide 1.0 mgBilateral medulla	1.00	—
Right medulla	1.00	—
Left medulla	1.00	—
PlaceboBilateral medulla	1.00	—
Right medulla	1.01	—
Left medulla	1.00	—

Treatment ratio1.0095% CI0.98 – 1.02p0.9335ANCOVA

Bilateral medulla: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Treatment ratio1.0095% CI0.98 – 1.01p0.6517ANCOVA

Right medulla: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Treatment ratio1.0095% CI0.98 – 1.02p0.9017ANCOVA

Left medulla: Responses are analysed using an ANCOVA with actual treatment, region and the stratification factors as categorical effects and the baseline value as a covariate.

Primary/protocol endpoint

Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Dependent Magnetic Resonance Imaging (BOLD MRI) (R2*)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Primary/protocol endpoint

Change in Kidney Oxygenation (Medulla), BOLD MRI (R2*)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Primary/protocol endpoint

Change in Global Kidney Perfusion (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Primary/protocol endpoint

Change in Kidney Inflammation (Cortex), Longitudinal Relaxation Time (T1) Mapping (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Primary/protocol endpoint

Change in Kidney Inflammation (Medulla), T1 Mapping (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Secondary/registry result

Change in Glomerular Basement Membrane Width (Kidney Biopsy)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Posted result

Group	Value (mean), Nanometer (nm)	95% CI
Semaglutide 1.0 mg	-72.67	—
Placebo	-8.66	—

Secondary/registry result/low confidence

Change in Apparent Diffusion Coefficient (ADC) (Cortex) (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

ratio, descriptive

Posted result

Group	Value (geometric_mean), Ratio of ADC (cortex)	95% CI
Semaglutide 1.0 mgBilateral cortex	1.00	—
Left cortex	1.01	—
Right cortex	0.98	—
PlaceboBilateral cortex	0.94	—
Left cortex	0.96	—
Right cortex	0.93	—

Secondary/registry result

Change in Apparent Diffusion Coefficient (ADC) (Medulla) (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Posted result

Group	Value (geometric_mean), Ratio of ADC (medulla)	95% CI
Semaglutide 1.0 mgBilateral medulla	0.98	—
Left medulla	0.99	—
Right medulla	0.98	—
PlaceboBilateral medulla	0.94	—
Left medulla	0.95	—
Right medulla	0.93	—

Secondary/registry result

Change in Mean Renal Artery Resistive Index (RARI) (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Posted result

Group	Value (geometric_mean), Ratio of RARI	95% CI
Semaglutide 1.0 mgBilateral renalartery	0.97	—
Right renalartery	0.98	—
Left renalartery	0.97	—
PlaceboBilateral renalartery	1.01	—
Right renalartery	1.01	—
Left renalartery	1.01	—

Secondary/registry result

Change in Albumin Excretion Rate (Urinalysis)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Posted result

Group	Value (mean), Milligrams per day (mg/d)	95% CI
Semaglutide 1.0 mg	-81.9	—
Placebo	-233.2	—

Secondary/registry result

Change in Kidney Function (Creatinine Clearance) (Urinalysis)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Posted result

Group	Value (mean), Milliliter per minute	95% CI
Semaglutide 1.0 mg	3.8	—
Placebo	-12.6	—

Secondary/protocol endpoint

Change in Glomerular Basement Membrane Width (Kidney Biopsy)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Secondary/protocol endpoint

Change in Apparent Diffusion Coefficient (ADC) (Cortex) (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, descriptive

Secondary/protocol endpoint

Change in Apparent Diffusion Coefficient (ADC) (Medulla) (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Secondary/protocol endpoint

Change in Mean Renal Artery Resistive Index (RARI) (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Secondary/protocol endpoint

Change in Albumin Excretion Rate (Urinalysis)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Secondary/protocol endpoint

Change in Kidney Function (Creatinine Clearance) (Urinalysis)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, improvement

Other (unclassified)

6 endpoints

Secondary/registry result/low confidence

Change in Gene Expression Assessed by Single Nucleus Ribonucleic Acid (RNA) Sequencing (Kidney Biopsy)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, descriptive

Posted result

Group	Value (number), log2 fold-change	95% CI
Semaglutide 1.0 mg/PlaceboCNT-2, RSPO3	3.468216523	—
CNT-Immune, SLC8A1-AS1	2.8531071	—
EC-GC-1, KCNK6	-1.952545192	—
EC-GC-1, EMC10	-2.485824696	—
EC-GC-1, ENSG00000286145	1.831300888	—
EC-GC-1, LMF1	-1.528463786	—
EC-GC-1, ANKUB1	1.783402404	—
EC-GC-1, AHNAK	-1.368952211	—
EC-GC-1, ENSG00000286150	1.318309657	—
EC-GC-1, NSUN6	-1.464540152	—
EC-GC-1, TFCP2L1	-2.24516792	—
EC-GC-1, ENSG00000274422	-1.860725608	—
EC-GC-1, DPYD-AS1	1.996950045	—
EC-GC-1, ENSG00000248138	2.110414741	—
EC-GC-1, ACSM2B	-1.785467699	—
EC-GC-1, CCNH	1.033873239	—
EC-GC-1, QTRT1	-2.415240141	—
EC-GC-1, CROCCP3	-1.254541813	—
EC-GC-1, ENSG00000251034	1.750285729	—
EC-GC-1, LSAMP	-2.439268964	—
EC-GC-1, LHX1-DT	-4.256689925	—
EC-GC-1, ESRRG	-1.527414037	—
EC-GC-1, CNTNAP2	-2.377391827	—
EC-GC-1, ENSG00000284966	1.665764749	—
EC-GC-1, BICC1	-1.445239386	—
EC-GC-1, GNA14-AS1	1.192645521	—
EC-GC-1, GUSBP11	-1.318511642	—
EC-GC-1, ENSG00000233783	1.668536087	—
EC-GC-1, SEMA6A-AS1	1.183886707	—
EC-GC-1, RBMS3-AS2	1.572052032	—
EC-GC-1, ENSG00000286147	-4.468841041	—
EC-GC-1, LINC00342	-1.151143461	—
EC-GC-1, IRF3	-1.566408786	—
EC-GC-1, ENSG00000249207	1.35685803	—
EC-GC-1, CRADD-AS1	1.972404772	—
EC-GC-1, TOX3	-2.206055055	—
EC-GC-1, ENSG00000286458	1.271036656	—
EC-GC-1, SLC12A3	-2.531722898	—
EC-GC-1, TALAM1	1.235573321	—
EC-GC-1, PCDH17	1.107442597	—
EC-GC-1, ATP13A3	1.078246118	—
EC-GC-1, ENSG00000231772	-2.382264501	—
EC-GC-1, FBXL19	-2.166973377	—
EC-GC-1, ENSG00000254420	1.74612131	—
EC-GC-1, SPC25	1.329461228	—
EC-GC-1, SMAD4	1.13655744	—
EC-GC-1, UFM1	1.20264148	—
EC-GC-1, ENSG00000259564	2.071724947	—
EC-GC-1, SHOC1	1.634369451	—
EC-GC-1, MEF2C-AS2	1.753288691	—
EC-GC-1, ENSG00000285801	1.440844025	—
EC-GC-1, FAM228B	-1.22996414	—
EC-GC-1, GLS	0.868999317	—
EC-GC-1, GDPD4	-6.564026305	—
EC-GC-1, INSYN2A	1.759769032	—
EC-GC-1, TNFRSF14	-1.254004029	—
EC-GC-1, PRX	-1.199880651	—
EC-GC-1, PNN	-1.024604708	—
EC-GC-1, KCNQ1OT1	-0.794847103	—
EC-GC-1, ACAP3	-1.44397269	—
EC-GC-1, BASP1-AS1	-4.83539932	—
EC-GC-1, RBFOX1	-1.706411849	—
EC-GC-1, CCDC90B-AS1	-1.678217382	—
EC-GC-1, ENSG00000240499	1.514399208	—
EC-GC-1, LINC03076	1.545248095	—
EC-GC-1, LINC01409	-1.022992954	—
EC-GC-1, CCT4	1.455396063	—
EC-GC-1, CDC73	0.802691458	—
EC-GC-1, NUMA1	-0.931923316	—
EC-GC-1, FLT4	-0.935590968	—
EC-GC-1, PDLIM5	0.764926487	—
EC-GC-1, SPCS3	1.02068757	—
EC-GC-1, ENSG00000250646	1.917331079	—
EC-GC-1, ENSG00000258168	1.083991656	—
EC-GC-1, ST8SIA4	0.901071433	—
EC-GC-1, BCL2L1-AS1	1.262413164	—
EC-GC-1, NRSN2-AS1	-1.275348201	—
EC-GC-1, STARD13-AS	1.148054491	—
EC-GC-1, CFLAR-AS1	1.168941896	—
EC-GC-1, PRKAR1A	1.257792414	—
EC-GC-1, ENSG00000226239	1.126077043	—
EC-GC-1, CTNNA3	-1.819759686	—
EC-GC-1, KCNK5	-2.491597199	—
EC-GC-1, ESR2	1.071576206	—
EC-GC-1, SLC25A46	1.062235788	—
EC-GC-1, REV3L	0.792446528	—
EC-GC-1, ZC2HC1C	2.027909336	—
EC-GC-1, ENSG00000279686	-1.453758633	—
EC-GC-1, ACER1	-5.256214457	—
EC-GC-1, MALRD1	-2.36001857	—
EC-GC-1, RRBP1	-0.837125744	—
EC-GC-1, ZNF451-AS1	1.853753635	—
EC-GC-1, SHANK2	-1.481833304	—
EC-GC-1, ENSG00000248388	2.196067138	—
EC-GC-1, KPNA5	0.936135624	—
EC-GC-1, APPAT	-1.750949862	—
EC-GC-1, PCNT	-0.932423432	—
EC-GC-1, ENSG00000233848	2.752498803	—
EC-GC-1, MORF4L2	1.28059543	—
EC-GC-1, ENSG00000236283	-1.572597604	—
EC-GC-1, SNRNP70	-0.883484114	—
EC-GC-1, EXD3	-0.805539835	—
EC-GC-1, CNTNAP5	-2.392758482	—
EC-GC-1, CASR	-2.323412555	—
EC-GC-1, ENSG00000285692	1.124516569	—
EC-GC-1, WDR81	-2.102548546	—
EC-GC-1, ZNF160	-0.907890266	—
EC-GC-1, CA12	-1.63720477	—
EC-GC-1, MAPK8IP3	-0.998528168	—
EC-GC-1, ABTB3	-2.945080572	—
EC-GC-1, CHORDC1	1.047593755	—
EC-GC-1, FREM1	-1.948982139	—
EC-GC-1, FXYD6-AS1	2.22442108	—
EC-GC-1, SPACA6	-1.045439073	—
EC-GC-1, AGBL1	-2.851170905	—
EC-GC-2, NES	-2.451444521	—
EC-GC-2, ADARB2	-3.212266234	—
EC-GC-2, SERPINB9	2.315559798	—
EC-GC-2, ENSG00000274422	-2.329265154	—
EC-GC-2, BTNL9	-2.01168798	—
EC-GC-2, CPEB2	1.51543417	—
EC-GC-2, TBX2	-2.604511077	—
EC-GC-2, ENSG00000290560	2.378813977	—
EC-GC-2, CFAP54	1.988387042	—
EC-GC-2, ABI3BP	1.57362138	—
EC-GC-2, SPACA6	-1.724379529	—
EC-GC-2, ADAMTSL2	-2.009897896	—
EC-GC-2, LZTS1	-2.659531511	—
EC-GC-2, ENSG00000285744	1.889210245	—
EC-GC-2, ENSG00000225689	-1.414674941	—
EC-GC-2, LUZP2	-4.384000321	—
EC-GC-2, NCKAP5	-1.592351284	—
EC-GC-2, FAT1	-1.855192898	—
NKC-NKT, AGBL4	-2.145446805	—
NKC-NKT, TFEC	1.989578132	—
NKC-NKT, ENSG00000254186	-2.913048038	—
NKC-NKT, PDE10A	-2.170777761	—
NKC-NKT, SHANK2	-2.431773845	—
PEC, RGS6	-3.331377896	—
PEC, AHNAK	-1.645129407	—
PT-2, LRRC4C	-2.167101922	—
PT-2, DSCAM	-3.104786855	—
PT-2, RCN3	-1.636040003	—

Secondary/registry result/low confidence

Change in Mean Arterial Flow (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

ratio, descriptive

Posted result

Group	Value (geometric_mean), Ratio of mean arterial flow	95% CI
Semaglutide 1.0 mgBilateral renalartery	0.96	—
Right renalartery	0.97	—
Left renalartery	0.96	—
PlaceboBilateral renalartery	0.96	—
Right renalartery	0.95	—
Left renalartery	0.98	—

Secondary/registry result/low confidence

Change in Natriuresis (Urinary Sodium Excretion) (Urinalysis)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, descriptive

Posted result

Group	Value (mean), Millimoles per day (mmol/day)	95% CI
Semaglutide 1.0 mg	-7.3	—
Placebo	-26.9	—

Secondary/protocol endpoint/low confidence

Change in Gene Expression Assessed by Single Nucleus Ribonucleic Acid (RNA) Sequencing (Kidney Biopsy)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in Mean Arterial Flow (MRI)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in Natriuresis (Urinary Sodium Excretion) (Urinalysis)

Time frame:Baseline (week 0), End of treatment (week 52)

change from baseline, descriptive

Publications (5)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide.
Kidney international2026 Jan (month)PMID41207620doi:10.1016/j.kint.2025.10.005via clinicaltrials gov reference derived + pubmed nct search
Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2025 Oct 30PMID40608494doi:10.1093/ndt/gfaf114via pubmed nct search
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
The Cochrane database of systematic reviews2025 Feb 18PMID39963952doi:10.1002/14651858.CD015849.pub2via clinicaltrials gov reference derived + pubmed nct search
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Clinical journal of the American Society of Nephrology : CJASN2025 Feb 1PMID39480988doi:10.2215/CJN.0000000584via clinicaltrials gov reference derived + pubmed nct search
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.
American journal of preventive cardiology2023 Jun (month)PMID37313358doi:10.1016/j.ajpc.2023.100502via pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.